Oruka Therapeutics’ (ORKA) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a report issued on Monday morning,Benzinga reports. They currently have a $45.00 price target on the stock.

Several other analysts have also recently commented on ORKA. Wedbush reiterated an “outperform” rating and issued a $40.00 target price on shares of Oruka Therapeutics in a report on Tuesday, November 19th. Leerink Partnrs upgraded Oruka Therapeutics to a “strong-buy” rating in a report on Tuesday, September 17th. Jefferies Financial Group began coverage on Oruka Therapeutics in a report on Friday, September 13th. They issued a “buy” rating and a $40.00 target price on the stock. Lifesci Capital began coverage on Oruka Therapeutics in a report on Monday, September 16th. They issued an “outperform” rating and a $41.00 target price on the stock. Finally, TD Cowen started coverage on Oruka Therapeutics in a report on Monday, September 16th. They issued a “buy” rating on the stock. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $43.17.

Oruka Therapeutics Price Performance

Shares of ORKA stock opened at $18.51 on Monday. The firm has a 50 day moving average of $26.02. Oruka Therapeutics has a one year low of $18.39 and a one year high of $53.88. The company has a market capitalization of $647.85 million, a PE ratio of -2.96 and a beta of 0.87.

Hedge Funds Weigh In On Oruka Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC acquired a new position in shares of Oruka Therapeutics during the third quarter worth approximately $343,000. The Manufacturers Life Insurance Company acquired a new position in shares of Oruka Therapeutics during the third quarter worth approximately $1,037,000. Wellington Management Group LLP acquired a new position in shares of Oruka Therapeutics during the third quarter worth approximately $2,013,000. Janus Henderson Group PLC acquired a new position in shares of Oruka Therapeutics during the third quarter worth approximately $5,840,000. Finally, Redmile Group LLC acquired a new position in shares of Oruka Therapeutics during the third quarter worth approximately $10,091,000. 56.44% of the stock is currently owned by institutional investors.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.